MedPath

A Comparison of OASIS Wound Matrix With Approved Dressings for Skin Graft Donor Sites

Phase 4
Withdrawn
Conditions
Skin Graft Complications
Registration Number
NCT02994589
Lead Sponsor
Loma Linda University
Brief Summary

The investigators objective is to compare OASIS wound matrix with other commonly used dressings available for the donor site in split thickness skin grafting in order to determine which dressing provides the best outcome based on pain level, time to healing and aesthetic outcome.

Detailed Description

Investigators seek to compare Oasis wound matrix with Tegaderm and Xeroform in order to determine whether advantages exist in one or more of the dressing types that are approved and currently used for split-thickness skin graft donor site dressings.

Patients will be randomly assigned to one of the three treatment groups and followed up post-operatively and treated as per current standard of care.

Data to be collected and analyzed includes: patient age, co-morbid illnesses, medication, skin-graft donor location, skin-graft donor area, STSG thickness, infection rate, complications involving the donor site, post-operative pain score every morning until hospital discharge, healing rate, photographs of the donor site immediately post-operatively and then at routine follow-up appointments.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • patients scheduled to undergo split thickness skin grafting
  • patients able to consent without a proxy
Exclusion Criteria
  • confounding medical conditions
  • previous skin grafting from site
  • prior use of biological skin substitute on site

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Primary Outcome Measures
NameTimeMethod
Time to Heal7-21 days

Patient will be followed up during routine post-operative appointments at the clinic weekly to check the healing process of the donor site wound.

Secondary Outcome Measures
NameTimeMethod
Aesthetic Outcome1-12 weeks

During routine followup visits to the clinic, the donor site aesthetic outcome will be observed and recorded clinically and digitally (photographs). The Vancouver Scar Scale will be used.

Pain intensity measure7 days

Self reported pain intensity in the morning and evening with activity over the past 7 days. Each item is scored on a scale of 0-10 (0= no pain, 10= highest intensity of pain)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.